ArticleNature communications2010
B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.
Article in Nature communications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 78 citations in OpenAlex.
- Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.The Lancet. Infectious diseases · 2015Trial
- Trial
- Use of principal components analysis and protein microarray to explore the association of HIV-1-specific IgG responses with disease progression.AIDS research and human retroviruses · 2014Trial
- B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.Journal of virology · 2012Trial
- Depletion and recovery of IgG following treatment with an anti-FcRn antibody and IdeS in pigtail macaques.Clinical and experimental immunology · 2026Article
- Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.bioRxiv : the preprint server for biology · 2025Article
- Adoptive B cell therapy for chronic viral infection.Frontiers in immunology · 2022Article
- Antibody-independent functions of B cells during viral infections.PLoS pathogens · 2021Review
- Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19.Immunological reviews · 2021Review
- Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.Frontiers in immunology · 2021Article
- Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.Nature communications · 2020Article
- Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans.Cell reports. Medicine · 2020Article
- Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab.Nature communications · 2019Article
- Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.Journal of virology · 2018Article
- T-bet-expressing B cells during HIV and HCV infections.Cellular immunology · 2017Review
- T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.JCI insight · 2017Article
- The HIV-1 transmission bottleneck.Retrovirology · 2017Article
- Use of broadly neutralizing antibodies for HIV-1 prevention.Immunological reviews · 2017Review
- Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.Nature reviews. Drug discovery · 2016Review
- Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus.Nature communications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
HIV can be partially contained by host immunity and understanding the basis of this may inform vaccine design. The importance of B-cell function in long-term control is poorly understood. One method of investigating this is in vivo cellular depletion. In this study, we take advantage of a unique opportunity to investigate the role of B cells in an HIV-infected patient. The HIV-1(+) patient studied here was not taking antiretroviral drugs and was treated for pre-existing low-grade lymphoplasmacytoid lymphoma by depletion of CD20+ B cells using rituximab. We demonstrate that B-cell depletion results in a decline in autologous neutralizing antibody (NAb) responses and a 1.7 log(10) rise in HIV-1 plasma viral load (pVL). The recovery of NAbs results in a decline in pVL. The HIV-1 sequences diversify and NAb-resistant mutants are subsequently selected. These data suggest that B-cell function can contribute to the long-term control of pVL, and that NAbs may be more important in controlling chronic HIV-1 infection than previously suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.